

Poractant (Curosurf)

BRAND Curosurf®

MANUFACTURER Chiesi

FORM Suspension 120mg/1.5ml AND 240mg/3ml

Two vial sizes available (Some units only keep 120mg vial)

INDICATION Treatment or prophylaxis of Respiratory Distress Syndrome (RDS) in preterm babies (See local policy for more information).

DOSE RANGE

AGE	DOSE	FREQUENCY	ROUTE
	<p>Initial dose:</p> <p>100-200mg/kg/dose (1.25-2.5ml/kg)</p> <p>Always administer whole vial sizes within dose range</p>	See Local guideline	By endotracheal tube (see local guideline for more details)

For prophylaxis (where the birthweight will not be known) one full 120 mg vial should be used. This will provide a dose of 100 -200 mg/kg for all babies weighing between 600g &1200g. See guideline for further information.

METHOD OF ADMINISTRATION

Administer via the endotracheal route in intubated infants, or through the Less Invasive Surfactant Administration (LISA) technique using a syringe (See local policy for further details)

CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS

- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

FURTHER INFORMATION

- No endotracheal suction, if possible, for 2 hours after dose is given.

STORAGE

- The product must be stored in a refrigerator at +2°C to +8°C, protected from light, until the moment of use.
- Do not use any residual quantity in the vial after the first aspiration.
- Unopened vials of Curosurf should be returned to the fridge as soon as possible. Vials that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. These vials should be marked to indicate it has been out of the fridge and the date written on the box. These vials cannot be warmed and returned to the fridge a second time. To avoid wastage these vials should be used for babies receiving a repeat dose in the Intensive care unit

LICENSED STATUS

Licensed for treatment of RDS in preterm infants > 700g birthweight. Licensed for prophylaxis in preterm infants 24 to 31 weeks estimated gestational age at risk of RDS or surfactant deficiency.

LINKS

[BNF for Children:](#) / [Electronic Medicines Compendium](#)

West of Scotland ORAL/ OTHER ROUTE Drug Monographs

APPLICABLE POLICIES

[West of Scotland Neonatal Guidelines:](#)

Consult local policy if applicable

Document Number:	002	Supersedes:	001
Prepared by:	WoS Neo Pharm group	Checked by	Marie L Stewart
Date prepared	Aug 2016	Date updated	October 2023
Updated by	Marie L Stewart	Review Date	October 2026

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications.
This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.
